Cardiff un­veils pos­i­tive Phase 2 da­ta for col­orec­tal can­cer drug, $40M of­fer­ing

Cardiff On­col­o­gy an­nounced an over­sub­scribed $40 mil­lion of­fer­ing on Tues­day af­ter it re­leased pos­i­tive da­ta from a mid-stage tri­al in­ves­ti­gat­ing its on­va­nsert­ib com­bo in pa­tients …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER